NUCIEN PHARMA(SH:688189)2025-01-21 12:10Financial Performance Forecast - The company expects a net loss attributable to shareholders of the parent company for 2024 to be between -260 million and -360 million yuan[4]. - The net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, is projected to be between -262 million and -362 million yuan for 2024[4]. - In 2023, the total profit was 7.6073 million yuan, with a net profit attributable to shareholders of the parent company of 3.7515 million yuan[5]. - The net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, was 11.0774 million yuan in 2023[5]. Market and Operational Challenges - The company has adjusted and optimized sales strategies due to industry policy environment and intensified market competition, leading to a decrease in sales prices for core products[6]. - The company has experienced a decline in operating income and gross margin due to fewer flu cases in the second, third, and fourth quarters of 2024[6]. Cost Management and Strategic Adjustments - The company has implemented cost reduction and efficiency improvement measures, resulting in a significant decrease in selling, administrative, and financial expenses compared to the previous year[7]. - The company plans to further adjust marketing strategies and enhance cost control to strengthen core competitiveness and respond to industry changes[7]. Earnings Forecast Reliability - There are no significant uncertainties affecting the accuracy of this earnings forecast[8]. - The preliminary financial data may differ from the final figures disclosed in the 2024 annual report[9].